Last-decade PCa research describes miR-375 as oncogenic and associated with metastatic castration-resistant PCa as well as with biochemical recurrence (defined as a rise in serum PSA levels following radical prostatectomy and/or radiation therapy). This evidence concerns the gene KLK3 and posterior cortical atrophy.